EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies

George Karun Kurian, Paolo Salvioni Chiabotti, Caroline Hall, Noemie Lejay, Jérémy Perriraz, Olivier Rouaud, Adrien Depeursinge, Marie Nicod Lalonde, Niklaus Schaefer, Gilles Allali, John O Prior iD, Mario Jreige

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07680-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von George Karun Kurian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Lewy Body Disease, Nortropanes, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Lausanne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Quantification of I-123-ioflupane uptake using modern SPECT/CT improves diagnostic accuracy for disorders affecting the nigrostriatal pathway. This study assessed whether absolute and relative standardized uptake values (SUV) could distinguish dementia with Lewy bodies (DLB) from non-DLB in patients with suspected DLB and explored associations with core clinical features, including visual hallucinations (VH) and REM sleep behavior disorder (RBD).

Methods

Seventy-four patients (mean age 71.5 ± 9.26 years; 39% female) were retrospectively included. All underwent I-123-ioflupane SPECT/CT imaging with both iterative (Flash 3D) and quantitative reconstructions. SUVmax, SUVmean, and relative SUV (rSUV) values were extracted for the caudate, putamen, and striatum. Uptake metrics were compared between DLB and non-DLB groups and analyzed in relation to clinical features, including visual hallucinations (VH) and REM sleep behavior disorder (RBD).

Results

Visual assessment classified 28/74 scans (38%) as abnormal (sensitivity 90%, specificity 80%, AUC 0.846). Quantitative SUVmax in the striatum and putamen showed the highest diagnostic performance (AUC up to 0.83). Striatal SUVmax remained an independent predictor of DLB in multivariable analysis (OR = 0.58, p = 0.003). Patients with VH had significantly lower striatal SUVmax than those without ( p = 0.004), with an optimal cutoff of ≤ 6.0 g/mL (AUC = 0.70, sensitivity 64.3%, specificity 80.4%). No significant differences were observed for RBD.

Conclusion

Quantitative I-123-ioflupane uptake assessment using SUV measures offers clinically relevant diagnostic value for differentiating DLB from other neurodegenerative diseases. It also helps in identifying patients with visual hallucinations, supporting the broader integration of SUV-based dopaminergic imaging into clinical workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body DiseaseNortropanesSingle Photon Emission Computed Tomography Computed TomographyHumansFemaleAgedMaleDiagnosis, DifferentialRetrospective StudiesMiddle AgedAged, 80 and overHallucinations

Stichwörter der Autor:innen

Dementia with lewy bodiesDopamine transporter imagingI-123-ioflupaneQuantitative imagingSPECT/CTSUV (standardized uptake value)Visual hallucinations

Substanzen

ioflupaneNortropanes

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Leenaards Memory Center, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Institute of Informatics, School of Management, HES-SO Valais-Wallis University of Applied Sciences and Arts Western Switzerland, Sierre, Switzerland.
  • Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. john.prior@chuv.ch.

ORCID-Profile: John O Prior

Förderung

  • University of Lausanne

Zitieren

APA

Kurian, G. K., Chiabotti, P. S., Hall, C., Lejay, N., Perriraz, J., Rouaud, O., Depeursinge, A., Nicod Lalonde, M., Schaefer, N., Allali, G., Prior, J. O., & Jreige, M. (2026). Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07680-7

Vancouver

Kurian GK, Chiabotti PS, Hall C, Lejay N, Perriraz J, Rouaud O, et al. Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07680-7

BibTeX
@article{Kurian2026,
  author = {Kurian, George Karun and Chiabotti, Paolo Salvioni and Hall, Caroline and Lejay, Noemie and Perriraz, Jérémy and Rouaud, Olivier and Depeursinge, Adrien and Nicod Lalonde, Marie and Schaefer, Niklaus and Allali, Gilles and Prior, John O and Jreige, Mario},
  title = {Contribution of quantitative I-123-ioflupane SPECT/CT to the differential diagnosis of dementia with lewy bodies},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07680-7}
}
Kostenlos starten →